JMP Securities analyst Silvan Tuerkcan initiated coverage of enGene (ENGN) with an Outperform rating and $18 price target enGene is a clinical-stage biotechnology company focused on developing novel ...

Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of ...